IB Times -- Bio-pharmaceutical firm Lipoxen’s revenues were below its expectations in the second half of 2009. It said this was due to a delay in the phase II clinical trials for long-acting EPO and Insulin which meant the potential licensing revenues accompanying these candidates did not materialise.
